Description
Recombinant Ebola Virus-like Particles (EBOV VLPs) are produced in mammalian HEK293 human cells, assembled with Envelope protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. EBOV VLPs can be used in the development of EBOV diagnostics and in vaccine development and R&D (including use as an immunogen).